What Should Be Known by a Urologist About the Medical Management of COVID-19’s Patients?
| Autor: | Matilde Sánchez Conde, Javier Burgos Revilla, Agustín Fraile Poblador, Belén Comeche, Vital Hevia, Luis López-Fando Lavalle, Alberto Medina, Sara Álvarez, Ana Domínguez Gutiérrez, Manuel Hevia Palacios, Alberto Esteban-Fernández, Álvaro Sánchez-González, Santiago Moreno-Guillén, Enrique Sanz Mayayo, Mercedes Ruiz, Javier Lorca Álvaro, Gemma Duque, Victoria Gómez Dos Santos |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Urology Pneumonia Viral 030232 urology & nephrology Context (language use) Review 03 medical and health sciences Betacoronavirus 0302 clinical medicine Multidisciplinary approach Pandemic Epidemiology medicine Humans Medical management Intensive care medicine Adverse effect Pandemics business.industry SARS-CoV-2 COVID-19 General Medicine Clinical trial Treatment Urologist 030220 oncology & carcinogenesis business Coronavirus Infections Kidney Diseases (G Ciancio Section Editor) |
| Zdroj: | Current Urology Reports |
| ISSN: | 1534-6285 1527-2737 |
| Popis: | Purpose of Review The alarming number of confirmed COVID-19 cases put a strain on the healthcare systems, which had to reallocate human and technical resources to respond to the emergency. Many urologists became integrated into multidisciplinary teams, dealing with this respiratory illness and its unknown management. It aims to summarize the epidemiological, clinical, diagnostical, and therapeutical characteristics of COVID-19, from a practical perspective, to ease COVID-19 management to non-physician staff. Recent Findings We performed a narrative review of the literature regarding COVID-19, updated to May 8th, 2020, at PubMed and COVID resource platforms of the main scientific editorials. COVID-19, characterized by fever, myalgias, dyspnea, and dry cough, varies widely from asymptomatic infection to death. Arrhythmias and thrombotic events are prevalent. Lymphopenia and inflammatory reactant elevation on laboratory, as well as bilateral and peripheral ground-glass opacities or consolidations on X-Ray, are usually found in its assessment. Little is known about SARS-CoV-2 immunology. To date, no therapy has demonstrated efficacy in COVID-19. Of-level or compassionate-use therapies are prescribed in the context of clinical trials. We should become familiar with specific adverse events and pharmacological interactions. Summary The COVID-19 pandemic has paralyzed the urological activity, and its long-term consequences are unpredictable. Despite not being used to deal with respiratory diseases, the urologists become easily qualified to manage COVID-19 by following protocols and being integrated into multidisciplinary teams, helping to overcome the pandemic. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink